GPX4 and cancer: Moreover, in the cancer field, direct inhibitors of GPX4 expression/activity have been actively searched and many compounds, now called Class-II FINs, have been proposed thus far (e.g., ML162, ML210, FIN56, FINO2, and RSL3), with promising results in vitro and in vivo [198,200].